Sun Pharmaceutical Industries announced that the Australian Therapeutic Goods Administration (TGA) has granted regulatory approval for Winlevi� (clascoterone cream 1%). Winlevi� is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older. As stated by Hellen de Kloet, Business Head � Western Europe, Australia and New Zealand, Sun Pharma �Winlevi� is an exciting addition to our expanding dermatology portfolio of innovative medicines in Australia. Winlevi`s novel mechanism of action will be a welcome addition to the physician`s toolkit while treating acne.� Diana Harbort, President of the Dermatology Division of Cosmo, said: �We are very pleased that Winlevi� will soon be available to patients in Australia. This is another achievement in the mission of Cosmo and Sun Pharma to improve the lives of patients affected by skin conditions.� Winlevi� will be available in Australia this June.Powered by Capital Market - Live News

Sun Pharmaceutical Industries has entered into an agreement with Surgimatix, Inc., pursuant to which Sun Pharma has agreed to acquire 16.33% shares of Surgimatix, Inc. for a cash consideration of USD 3.05 million. Surgimatix, Inc., is a company incorporated in the State of Michigan, having its headquarters and registered office at Illinois, US. The Company is engaged in the business of developing a proprietary soft tissue fixation device for laparoscopic hernia repair and other minimally invasive surgeries. Surgimatix, Inc., is yet to commence its commercial operations. Powered by Capital Market - Live News

Sun Pharmaceutical Industries announced that it has been included in the S&P Global Sustainability Yearbook 2024. Within respective industries, this Yearbook aims to distinguish those companies that have demonstrated strengths in corporate sustainability.This recognition attests to Sun Pharma`s commitment to incorporate Environmental, Social, and Governance (ESG) principles through focused initiatives across its businesses.Powered by Capital Market - Live News

Net profit of Sun Pharmaceuticals Industries rose 16.52% to Rs 2523.75 crore in the quarter ended December 2023 as against Rs 2166.01 crore during the previous quarter ended December 2022. Sales rose 9.52% to Rs 12156.86 crore in the quarter ended December 2023 as against Rs 11100.14 crore during the previous quarter ended December 2022. ParticularsQuarter Ended�Dec. 2023Dec. 2022% Var. Sales12156.8611100.14 10 OPM %28.6027.06 - PBDT3692.303131.42 18 PBT3070.162471.47 24 NP2523.752166.01 17 Powered by Capital Market - Live News

Sun Pharmaceuticals Industries announced that the Board of Directors of the Company at its meeting held on 31 January 2024, has recommended a Interim dividend of Rs.8.5 per share (i.e.850%), subject to the approval of the shareholders.Powered by Capital Market - Live News